Home / Transcripts / American Vanguard Corporation (AVD) · March 16, 2026

American Vanguard Corporation (AVD) Earnings Call Transcript

March 16, 2026

New York Stock Exchange US Materials Chemicals earnings 30 min

Earnings Call Speaker Segments

Anthony Young executive
#1

Thanks, operator. Hello everyone, and thanks for joining us for the review of American Vanguard's results for the full year 2025. Dak Kaye, our Chief Executive Officer, and David Johnson, our Chief Financial Officer, will deliver the prepared comments. Once those comments wrap up, we'll take questions on the call. Today's press release and the supplemental slides can be found on our website. A webcast replay and a transcript of this event will be posted to our website not long after the call concludes. Prior to starting our presentation, we want to remind you that non-GAAP figures and forward-looking statements appear in today's press release and in certain remarks made during this call, and actual results could differ materially from these forecasts. Please see the cautionary language in our press release and slides, as well as the risk factors outlined in our SEC filings, all of which can be accessed on our website. I'll now hand the call over to our CEO, Dak Kaye.

Douglas Kaye executive
#2

Thank you, Anthony, and hello everyone joining our fourth quarter 2025 earnings conference call. Although 2025 proved difficult for agriculture as a whole, I feel good about what has been accomplished at American Vanguard. Our business, operational, digital, and organizational programs have all been put into action; we've brought aboard skilled, seasoned staff members, safety measurements have gotten better in every area, our team has concentrated on creating new products, and at the same time we've cut back on manufacturing and operating expenses. During 2025 these gains showed up in our results, yet even more significantly, they are setting the company up for success over the long haul. On top of that, for more than a year, the team has concentrated on locating a capital structure enabling us to pay down our expiring credit facility while offering the greatest possible financial flexibility for growth ahead; we feel we've landed on the correct answer by way of two term loans — one provided by Centerbridge Partners and one from the existing BMO-led Syndicate. You can find complete information about these term loans in our SEC filings. Even though on average we're now paying interest at a higher rate than under our prior revolving credit facility, we have a substantial runway ahead to keep enhancing operations and to demonstrate to the investment community the greater earnings power that I believe is achievable. Beyond that, the team is now entirely concentrated on operating the business and producing the sales and margins we anticipate. As we work to set the company up for what lies ahead, we've decided to rationalize the Los Angeles manufacturing facility. The company's oldest site is the L.A. plant, and under present conditions it can no longer compete. We extend our thanks to the American Vanguard team members at this location for their exceptional service and commitment to operating a safe facility throughout the years it was in operation. We intend to assist many of them as they pursue the next steps in their careers, yet for the broader company to stay competitive, taking this extremely hard step was unavoidable. Moving additional volumes through our Axis, Alabama site will let this rationalization save the company no less than $4 million each year, and we anticipate better utilization there, which will likewise enhance our cost absorption and, in the end, our profitability. As previously announced, the company will relocate its global headquarters from Newport Beach to a smaller, more cost-effective space in Irvine, California; we estimate roughly $0.5 million in annual savings from this move, which will also let our corporate team work in a more collaborative, modern office environment. We anticipate that both the L.A. facility rationalization and the headquarters relocation will wrap up by the close of the second quarter of this year. For us these represent two major milestones, though not the final ones, since we will keep working to enhance the company's cost structure. Now to the 2025 results. The company produced $39.2 million of adjusted EBITDA, a touch above what we delivered the year before. Weak fourth-quarter sales kept us from hitting our adjusted EBITDA goal of $40 million to $44 million. Even so, we managed to trim expenses beyond what we had originally projected, and we finished a joint development agreement, which helped make up for some of the sales shortfall. The supply chain and logistics group we brought on board a year ago keeps discovering ways to bring down what we pay for materials, and it has also made our warehousing and freight costs better; those gains came through even ahead of the rollout of our new software systems, which are slated to be fully deployed later this year and ought to let us push inventory and raw material costs down even more. My expectation is that inventory turns will rise in 2026 and beyond as we push toward a target of 2.25 turns; beyond helping gross profit, I also anticipate that this will reduce the working capital we need to run the business. Keeping costs in check has ranked at the top of our priorities, yet it's equally worth stressing that American Vanguard has a growth story too. During earlier conference calls, I've mentioned how the development portfolio caught me off guard when I came aboard. Since then, we've made moves to strengthen that area while still keeping a careful watch on our R&D spending. Our presentation contains a chart showing this renewed emphasis on product development. One new product, Duro-LQ, already launched in 2026, and altogether we anticipate rolling out five new products across North America during this year. We also have a set of new registrations coming internationally. As we widen our registration footprint and lengthen product lifetimes across multiple jurisdictions, our goal is to register no fewer than 25 new products in North America by 2031. Because new products generally deliver a bigger margin contribution than what's already in the portfolio, getting them to market will lift revenue and improve our margin profile. The bottom line: over the medium term, we figure we can bring in at least an extra $100 million in yearly revenue worldwide from new products currently at various stages of development. Beyond new products, we also intend to respond even better to what our customers need. I'm confident we can move more volume through our factories by improving how well we listen to our customers. That's partly why we named a new Chief Commercial Officer, Mike DiPaola. Mike adds 30 years of ag experience along with an enthusiasm and aggressiveness our commercial operation had been lacking. As factory utilization rises, we're able to spread fixed costs across more units, which boosts profitability. Now I'll turn to what we've been seeing in the wider agricultural economy. The industry still hasn't bounced back from a downturn that began in 2023. Agricultural commodities are bouncing back from those weak points we saw in the summer of 2025, though they're still far beneath what industry watchers would call normal for this market historically. It does look like the worst of the destocking across the industry has passed us, yet distributors aren't showing any real appetite to build their inventories back up. After multiple years of low commodity prices, farmer liquidity is something that worries us. When it comes to acreage, forecasts show cotton and corn both dipping a bit, whereas soybeans are expected to rise. Taking everything together, the folks who observe this industry anticipate a fairly steady year in terms of what gets planted. Worth pointing out — growers are delaying their crop choices until the last moment more than we've ever seen, and geopolitical matters play a big role in shaping those calls. There are a few positive signs: farmer support payments appear to be getting distributed, and when oil prices climb, that tends to boost demand for biofuels made from corn as well as soybeans. On top of that, pricier oil raises the cost of synthetic fabrics, which pushes more demand toward cotton. Before I share our 2026 targets, I want to call attention to something that hurt our financial results. Normally, American Vanguard brings in a large amount of cash during Q4 from our customers — an industry pattern we've long called prepaid. This approach is used throughout the industry by most of our customers along with our competitors. Because one competitor faced financial pressure, the channel stepped away from prepay programs market-wide. That's caused our nominal debt levels to rise compared with a year ago, since we usually use that capital to reduce debt at the end of the year. David will cover this further in his prepared remarks. While we hold out for the agricultural economy to get better, our business improvement plan ought to let us lift adjusted EBITDA relative to 2025. For 2026, we're projecting adjusted EBITDA between $44 million and $48 million, with sales ranging from $530 million to $550 million. We're eager about the chance for stronger results in the years ahead as we keep rolling out new products; we think future earnings power is much greater and will let the company bring down its debt and put money into areas that drive long-term growth. At this point I'll hand the call over to our CFO, David Johnson. David?

David Johnson executive
#3

Thank you, Dak. Hello, everyone, and good afternoon. To begin, I'd like to recognize the team for the extraordinary work that made it possible to complete the debt refinancing. After examining numerous structures and consulting with a broad set of players throughout the financing sector, we settled on a term loan arrangement that avoids any equity dilution, provides steadiness during challenging market conditions, and gives us room to reduce our debt as performance improves. Turning to a second piece of good news, I'm pleased to report that all of the material weaknesses identified in the 2024 audit have now been resolved — an enormous undertaking alongside the refinancing and the standard audit workload; accomplishing that in such a short period is truly remarkable. We're glad to announce that our Form 10-K for 2025 is being submitted today; now let me turn to our 2025 financial results. Revenue for 2025 reached $515 million, compared with $547 million a year earlier, representing a 6% decrease. That came in slightly below the $520 million to $535 million range we had targeted. Sales from international operations dropped 14%, driven by high channel inventories in Mexico and an ongoing drought in Australia, while U.S. crop business sales matched the prior-year period. More encouragingly for the U.S. crop business, destocking seems to have mostly worked its way through, and product sitting in the field is now about equal to our sales, indicating a low level of channel inventory domestically; even so, customers have yet to show they're ready to build stock and resume just-in-time purchasing. Specialty sales increased 10%, driven by securing a joint development agreement, our business-to-business sales, and expansion in our mosquito vector solutions. Our gross profit margin is trending favorably, rising to 29% in 2025. At the same time, OpEx as a share of sales dipped modestly to 27%. Thanks to certain initiatives we're undertaking, we expect further improvement in 2026 and beyond on both measures. For the full year 2025, adjusted EBITDA was $39.2 million, versus $39.1 million a year earlier. Our cost containment efforts were partially offset by weaker sales conditions, though better manufacturing performance provided a boost. Now to our balance sheet. The largest single obstacle we encountered as 2025 ended was how prepay compared with 2024. The company collected about $50 million less in prepay during 2025, which left us carrying somewhat more debt at year-end. We plan to further lower our net working capital this year and continue that effort going forward. Additionally, we are targeting a reduction of $40 million. From my perspective, we can operate this company more efficiently moving forward, because of the experienced supply chain leaders who joined us in 2025, and likewise as a result of modern management approaches and software solutions that are currently being implemented, which will enable quicker reactions to shifts occurring within the industry. Regarding capex, we spent approximately $4 million across 2025. Our spending in 2026 will most likely exceed that figure, but it ought to remain inside the range of $5 million to $10 million. That said, I'll turn it back to Dak.

Douglas Kaye executive
#4

Thank you, David. Before we turn things over for questions, I'd like to spend a moment looking back on what has been a difficult yet transformative year for American Vanguard. As the majority of you are aware, 2025 marked my first complete year with the company. The final slide in the presentation, called Plan 2030, illustrates where American Vanguard stood and where it is headed. As these objectives are met, I believe higher revenue, improved EBITDA and greater cash flow will be the result. To wrap up, I want to express my gratitude to the team for all the hard work that was accomplished in 2025. But I also want to push everyone to do even more in 2026, since I believe a bright future still lies ahead of us; with that, I'll open the call to questions. Operator?

Mike Harrison analyst
#5

I'd like to start by talking about Q4, which fell short of expectations on both the revenue line and the EBITDA line. From what I understand, most of that shortfall came from the international side, but I'm hoping you can give us some additional detail about what caused revenue to decline. And when it comes to the margin performance, did that match what you had anticipated, and was the EBITDA shortfall purely the result of lower revenue, or did cost-side problems also play a role?

Douglas Kaye executive
#6

All right. Mike, thanks for asking. Yes, I mean, it involved both international and domestic. What I'd say is that the domestic piece was mostly the result of the U.S. On the crop side, reduced potato acreage hurt metam sales, and demand for those products—metam in particular—was a factor too. Insecticides in the U.S. also came in lower. That said, our herbicide business showed some encouraging gains thanks to Zalo, which was a significant bright spot and contributed meaningfully during the fourth quarter. Outside the U.S., the situation ties mainly to the drought in Australia, as David noted, along with channel inventory in Mexico, where the destocking process hasn't progressed as far as it has in the U.S. When it comes to containing costs, I believe we performed quite well in Q4. We also kept our production costs in a solid position during Q4, and we're still making progress on that front. I'd say we're managing what's within our power and managing it effectively, so during the fourth quarter we saw gains in both expense management and production efficiency.

Mike Harrison analyst
#7

Sure. Regarding your long-term transformation plans, those have existed for some time now. I'm just wondering how the shutdown in L.A. and the move of the headquarters factor into that? Were those — did those get considered back when you first introduced this 15% EBITDA margin target, or ought we to view them as perhaps speeding up the path toward hitting that 15% target?

Douglas Kaye executive
#8

That's a fair question. When I initially joined, neither of those was directly included in the transformational plan. As we shifted the transformation plan into our business improvement plan, our business improvement initiatives, the rationalization of the L.A. facility grew clearer as we began examining our capacity utilization throughout the company and began putting together plans to shift production out of the LA site through the access site; so that wasn't originally included in the initial transformation plan, and neither was relocating the office, the headquarters. So these are initiatives we've pursued after the transformational plan. The initial transformational plan did include some very strong elements concerning the digital transformation, commercialization, rationalization of product portfolio and rationalization of our changes in our go-to-market structure in different areas around the world, particularly in Brazil, and some in Central America as well as our growth strategy for our specialty, our non-crop business. Those remain ongoing, together with various other initiatives that emerged from that. Did I answer the question, Mike?

Mike Harrison analyst
#9

Yes. That works well. Then I had, I suppose, a couple of items about cash flow and about how the debt is structured moving ahead. It's excellent to see that the new term loans are in the plan — are now in place. Still, I'm wondering: does any cash come in from shutting the Los Angeles facility, or from the headquarters move?

Douglas Kaye executive
#10

By proceeds, do you mean those from selling it, or from the...

Mike Harrison analyst
#11

Is there any property, land, or other holdings you could divest?

Douglas Kaye executive
#12

Actually, no — the L.A. site will keep running as a place for formulation and warehousing moving forward. Operations there will just happen on a far, far smaller scale. Initially, at least, nothing is being sold. Down the line, once we reach that stage, some equipment might be sold. Right now, though, we have no plans to sell any equipment at that location, though that could change later. Regarding the office space, we had leased it, the rent ran high, and frankly it wasn't well suited to conducting business — too spread out. That's why I genuinely can't wait to relocate into the new headquarters, a space built for more collaborative, modern ways of working for the team. It's just — it's located further out in Irvine, and I'm eager for that. Aside from the headquarters, though, no proceeds come in from this — there's $0.5 million in savings from the lease, and once L.A. is factored in, the net annual savings going forward come to roughly $4 million.

Mike Harrison analyst
#13

Got it, that makes sense. All right. Now, regarding cash flow — I realize prepayments came in unusually low during Q4, and that ended up weighing on how cash flow looks for '25. But what I'm wondering about is, with the software you intend to launch, plus what you're expecting from working capital in 2026, could free cash flow actually turn positive that year, assuming CapEx lands somewhere between $5 million and $10 million?

Douglas Kaye executive
#14

Yes, Mike, I think that's achievable. That's — yes, I do think so. Looking at our adjusted EBITDA projections and subtracting our interest, along with CapEx, we ought to find ourselves in a favorable cash flow position for 2026.

Rosemarie Morbelli analyst
#15

Dak, I had a question about that $100 million figure you mentioned for the midterm, which is supposed to come from new products. Looking at your slides right now, only a single example is shown, and that's Bullhorn insecticide. Could you share a bit more about what you're expecting? In other words, will these new products also include fungicides or herbicides? Also, how do you define midterm?

Douglas Kaye executive
#16

Those are great questions, Rosemarie. Additional products are on the way, and as I said, they're primarily going to come from insecticides and herbicides. Given the company's history, those are the main areas of focus, since we're taking the assets we currently hold and using them moving forward with new formulations and new products — that's the source of these new products. For classification purposes, a new product is defined as being less than 5 years from launch; that's the definition we'll use. The — and what was the second part of your question?

Rosemarie Morbelli analyst
#17

Well, I was just thinking about this — $100 million, versus what you're currently expecting for revenue next year at the midpoint, which is $540 million. That's quite a large jump. So what I'd like to know is, first, how at ease are you feeling about that $100 million figure? And second, when would it happen? You mention midterm — could you put a number on what midterm means?

Douglas Kaye executive
#18

Yes. Regarding the $100 million, I have confidence in it, though it has been somewhat tempered by what I've learned from my own experience with products — specifically with getting products to the point of launch. So the $100 million is something I feel good about. As for medium term, what we mean by that is roughly 2030 to 2031. So it isn't imminent, as I've said on earlier calls — we found ourselves in a position where we need to launch, or get a new product ready to launch. Typically, you need at least around 3 years to work through the regulatory pathway and end up with a registered product that can be marketed and sold; so from the creation of an idea to registration, that's three years. Because of where our organization's attention was directed — on the SIMPAS technology — we've been on hold; in fact, in '25 we launched only one product in the U.S. Beyond that, things have been fairly sparse. That explains why we expect new product sales to begin rising in '27 and '28 — with the bulk coming in '28, as we bring these products into the portfolio for launch.

Rosemarie Morbelli analyst
#19

Alright, that's quite useful. You mentioned the company's strong potential for future earnings. Right now, if we take the midpoint of the 2026 expectations, your EBITDA margin sits at roughly 8.5%. So, how much higher could that go? And besides all the measures you're taking to bring costs down, what level of top line growth is required to reach that?

Douglas Kaye executive
#20

That's a fair question. For the long term, we've maintained a consistent target of reaching 15%, and that remains our aim. A great deal needs to materialize for us to achieve it — not just pushing sales upward by about 4% to 6%, Dave, would you agree, our plan includes 4% to 6%.

David Johnson executive
#21

Yes.

Douglas Kaye executive
#22

When it comes to our CAGR, along with cutting costs or keeping them where they are, I still view 27% as quite elevated, or comparatively elevated, particularly given who we are and our position within the crop protection industry model. So either through higher sales, or through lower costs — or some mix of the two — we need to bring that down. On manufacturing efficiencies, I believe the capability is there. The team will keep demonstrating progress on that front, simply because of how intensely Nolteanous' group in manufacturing and Jerry's group in operations are concentrating on cost control and improved planning. Together, those efforts will lift our profitability at the gross profit line.

Douglas Kaye executive
#23

Yes, to wrap things up, I'd like to say that by doing what's needed to streamline our manufacturing operations, zeroing in on developing new products, building demand for what we make through listening to our customers, and always keeping an eye on our costs, we'll drive higher sales, improved profitability, and stronger cash flow, which delivers lasting value for our shareholders; and with that, thank you for the time you've given us today. Have a great day.

Operator operator
#24

Thanks. That brings today's call to a close, and you're free to hang up now. We appreciate everyone for joining.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Vanguard Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to American Vanguard Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.